Core Viewpoint - Federal Pharmaceutical's stock has seen an increase of over 3%, currently trading at 13 HKD, with a transaction volume of 50.78 million HKD, following the announcement of positive clinical trial results for its innovative drug UBT251 [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., has completed Phase II clinical trials of its self-developed innovative drug UBT251 injection in overweight/obese patients in China [1] - The Phase II weight loss data for UBT251 (GLP-1/GIP/GCGR) has shown impressive results, with a superior weight loss rate at lower doses compared to Eli Lilly's retatrutide over 24 weeks [1] - The safety profile of UBT251 indicates mostly mild to moderate gastrointestinal reactions, suggesting a favorable safety profile for the drug [1] Group 2: Market Outlook - Huatai Securities expresses optimism regarding the strong Phase II data from China, which may enhance the certainty of global Phase II data recently initiated by Novo Nordisk, indicating a positive outlook for UBT251's overseas sales potential [1]
港股异动 | 联邦制药(03933)涨超3% UBT251国内II期减重数据整体表现惊艳 机构看好其海外销售空间